Clinical research on cell therapy involving the administration of a patient's own immune cells has been made possible for patients with terminal colorectal cancer, who are difficult to treat. According to the Ministry of Health and Welfare on the 23rd, out of three clinical research implementation plans submitted by regenerative medical institutions during the 11th Advanced Regenerative Medicine and Advanced Biopharmaceuticals Deliberation Committee meeting held the previous day, one colorectal cancer cell therapy project was deliberated and passed as "suitable."

The project deemed suitable is a medium-risk cell therapy clinical study that sequentially administers the patient's own T lymphocytes and natural killer cells to patients with metastatic and recurrent terminal colorectal cancer.

Metastatic and recurrent terminal colorectal cancer is a stage 4 condition where cancer has spread to organs such as the liver, lungs, and peritoneum, leaving no appropriate treatments available. In this study, natural killer cells and T lymphocytes—which are immune cells—will be isolated from the blood of terminal colorectal cancer patients who have failed standard treatments such as resection and targeted chemotherapy, cultured for a certain period, and then administered.

Subsequently, the safety of the treatment will be confirmed, and evaluations will be conducted on indicators such as the proportion of patients whose cancer progression was suppressed or whose tumor size decreased, and the duration for which the cancer remained stable without worsening. If the therapeutic efficacy is confirmed, it is expected to provide a new option of personalized immune cell therapy for terminal colorectal cancer patients who have no further alternative treatments.

[Copyright (c) Global Economic Times. All Rights Reserved.]